Related Experiment Video

Updated: Jun 18, 2025

Induction and Testing of Hypoxia in Cell Culture
07:01

Induction and Testing of Hypoxia in Cell Culture

Published on: August 12, 2011

84.8K

CDK5RAP3 Inhibition by Hypoxia Activates P38MAPK to Facilitate Angiogenesis

Mengmeng Zhang1,2, Liu Yang3, Jun Shu1

  • 1Department of Plastic and Reconstructive Surgery, Chinese PLA General Hospital.

International Heart Journal
|July 31, 2024
PubMed

Insights

CDK5RAP3, a tumor suppressor, inhibits angiogenesis by reducing vascular endothelial growth factor (VEGF) under hypoxia. Its downregulation promotes VEGF, enhancing blood vessel formation.

Area of Science:

  • Molecular Biology
  • Cell Biology
  • Oncology

Background:

  • CDK5RAP3 acts as a tumor suppressor by inhibiting cell cycle kinases (Chk1, Chk2) and activating p53, crucial for apoptosis.
  • CDK5RAP3 also modulates p38 MAPK pathway activity, impacting cellular stress responses.

Purpose of the Study:

  • To investigate the antiangiogenic potential of CDK5RAP3.
  • To elucidate the molecular mechanisms of CDK5RAP3 in regulating angiogenesis in human umbilical vein endothelial cells (HUVECs) under hypoxia.

Main Methods:

  • HUVECs were subjected to hypoxic conditions (2% O2) to induce angiogenesis.
  • Vascular endothelial growth factor (VEGF) was used to stimulate angiogenesis.
  • Levels of CDK5RAP3, p38MAPK phosphorylation, and VEGF secretion were measured.
  • Cell proliferation, migration, and tube formation assays were performed using hypoxic conditioned medium (HCM).

Main Results:

  • Hypoxic conditions led to a time-dependent decrease in CDK5RAP3 levels in HUVECs.
  • Reduced CDK5RAP3 correlated with increased p38MAPK phosphorylation and activation.
  • Moderate hypoxia significantly increased VEGF secretion.
  • HCM enhanced HUVEC proliferation, migration, and tube formation.

Conclusions:

  • Moderate hypoxia promotes angiogenesis by inhibiting CDK5RAP3 expression in endothelial cells.
  • CDK5RAP3 plays a critical role in vascular regeneration, with its downregulation enhancing VEGF synthesis and endothelial cell functions.
  • CDK5RAP3 demonstrates potential as an antiangiogenic agent for conditions involving aberrant angiogenesis, such as cancer, ischemic diseases, and wound healing.
Keywords:
Human umbilical vein endothelial cellVEGF

More Related Videos

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:39

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

54
Co-immunoprecipitation Assay Using Endogenous Nuclear Proteins from Cells Cultured Under Hypoxic Conditions09:17

Co-immunoprecipitation Assay Using Endogenous Nuclear Proteins from Cells Cultured Under Hypoxic Conditions

Published on: August 2, 2018

18.1K

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.5K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.3K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.2K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K